Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1998 2
1999 3
2000 2
2001 1
2002 3
2003 2
2004 3
2005 4
2006 4
2007 3
2008 3
2009 3
2010 1
2011 4
2012 5
2013 3
2014 5
2015 3
2016 8
2017 14
2018 13
2019 11
2020 8
2021 6
2022 8
2023 2
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

110 results

Results by year

Filters applied: . Clear all
Page 1
Reply.
Durand-Zaleski I, Bulsei J, Seror O, Nahon P. Durand-Zaleski I, et al. Among authors: seror o. Hepatology. 2017 Jul;66(1):300-301. doi: 10.1002/hep.29193. Epub 2017 May 26. Hepatology. 2017. PMID: 28380685 No abstract available.
Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab.
Limousin W, Laurent-Puig P, Ziol M, Ganne-Carrié N, Nahon P, Ait-Omar A, Seror O, Sidali S, Campani C, Blanc P, Lermine A, Marisa L, Zucman-Rossi J, Nault JC. Limousin W, et al. Among authors: seror o. J Hepatol. 2023 Dec;79(6):1450-1458. doi: 10.1016/j.jhep.2023.08.017. Epub 2023 Aug 28. J Hepatol. 2023. PMID: 37647991
Optimizing curative management of hepatocellular carcinoma.
Nahon P, Vibert E, Nault JC, Ganne-Carrié N, Ziol M, Seror O. Nahon P, et al. Among authors: seror o. Liver Int. 2020 Feb;40 Suppl 1:109-115. doi: 10.1111/liv.14345. Liver Int. 2020. PMID: 32077602 Review.
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aubé C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L, Chatellier G; SARAH Trial Group. Vilgrain V, et al. Lancet Oncol. 2017 Dec;18(12):1624-1636. doi: 10.1016/S1470-2045(17)30683-6. Epub 2017 Oct 26. Lancet Oncol. 2017. PMID: 29107679 Clinical Trial.
Reply.
Nahon P, Seror O, Durand-Zaleski I. Nahon P, et al. Among authors: seror o. Hepatology. 2017 Jul;66(1):298-299. doi: 10.1002/hep.29174. Epub 2017 May 26. Hepatology. 2017. PMID: 28318039 No abstract available.
Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma.
Nault JC, Martin Y, Caruso S, Hirsch TZ, Bayard Q, Calderaro J, Charpy C, Copie-Bergman C, Ziol M, Bioulac-Sage P, Couchy G, Blanc JF, Nahon P, Amaddeo G, Ganne-Carrie N, Morcrette G, Chiche L, Duvoux C, Faivre S, Laurent A, Imbeaud S, Rebouissou S, Llovet JM, Seror O, Letouzé E, Zucman-Rossi J. Nault JC, et al. Among authors: seror o. Hepatology. 2020 Jan;71(1):164-182. doi: 10.1002/hep.30811. Epub 2019 Aug 12. Hepatology. 2020. PMID: 31206197
[Cranial pachymeningitis].
Fain O, Seror O, Wirth JF, Heron C, Mathieu E, Chamouard JM, Guillevin L, Thomas M. Fain O, et al. Among authors: seror o. Rev Med Interne. 1999 Mar;20(3):234-46. doi: 10.1016/s0248-8663(99)83051-3. Rev Med Interne. 1999. PMID: 10216880 Review. French.
110 results